139 related articles for article (PubMed ID: 14611676)
21. Expression of VEGF-A/C, VEGF-R2, PDGF-alpha/beta, c-kit, EGFR, Her-2/Neu, Mcl-1 and Bmi-1 in Merkel cell carcinoma.
Brunner M; Thurnher D; Pammer J; Geleff S; Heiduschka G; Reinisch CM; Petzelbauer P; Erovic BM
Mod Pathol; 2008 Jul; 21(7):876-84. PubMed ID: 18408656
[TBL] [Abstract][Full Text] [Related]
22. Coexpression of EGFR and HER-2 in pancreatic ductal adenocarcinoma: a comparative study using immunohistochemistry correlated with gene amplification by fluorescencent in situ hybridization.
Dancer J; Takei H; Ro JY; Lowery-Nordberg M
Oncol Rep; 2007 Jul; 18(1):151-5. PubMed ID: 17549361
[TBL] [Abstract][Full Text] [Related]
23. Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study.
Ooi A; Takehana T; Li X; Suzuki S; Kunitomo K; Iino H; Fujii H; Takeda Y; Dobashi Y
Mod Pathol; 2004 Aug; 17(8):895-904. PubMed ID: 15143334
[TBL] [Abstract][Full Text] [Related]
24. Functional role of ALK-related signal cascades on modulation of epithelial-mesenchymal transition and apoptosis in uterine carcinosarcoma.
Inoue H; Hashimura M; Akiya M; Chiba R; Saegusa M
Mol Cancer; 2017 Feb; 16(1):37. PubMed ID: 28193280
[TBL] [Abstract][Full Text] [Related]
25. Molecular markers for novel therapeutic strategies in pancreatic endocrine tumors.
Gilbert JA; Adhikari LJ; Lloyd RV; Halfdanarson TR; Muders MH; Ames MM
Pancreas; 2013 Apr; 42(3):411-21. PubMed ID: 23211371
[TBL] [Abstract][Full Text] [Related]
26. The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer.
Sheng Q; Liu J
Br J Cancer; 2011 Apr; 104(8):1241-5. PubMed ID: 21364581
[TBL] [Abstract][Full Text] [Related]
27. Expression of EGFR, HER-2/neu and KIT in germ cell tumours.
Durán I; García-Velasco A; Ballestín C; García E; Martínez-Tello F; Pond GR; García-Carbonero R; Cortés-Funés H; Paz-Ares L
Clin Transl Oncol; 2010 Jun; 12(6):443-9. PubMed ID: 20534400
[TBL] [Abstract][Full Text] [Related]
28. Clinicopathological analysis of c-kit expression in carcinosarcomas and leiomyosarcomas of the uterine corpus.
Winter WE; Seidman JD; Krivak TC; Chauhan S; Carlson JW; Rose GS; Birrer MJ
Gynecol Oncol; 2003 Oct; 91(1):3-8. PubMed ID: 14529656
[TBL] [Abstract][Full Text] [Related]
29. Analysis of EGFR, HER2, and TOP2A gene status and chromosomal polysomy in gastric adenocarcinoma from Chinese patients.
Liang Z; Zeng X; Gao J; Wu S; Wang P; Shi X; Zhang J; Liu T
BMC Cancer; 2008 Dec; 8():363. PubMed ID: 19061514
[TBL] [Abstract][Full Text] [Related]
30. Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma.
Santin AD; Bellone S; Van Stedum S; Bushen W; Palmieri M; Siegel ER; De Las Casas LE; Roman JJ; Burnett A; Pecorelli S
Cancer; 2005 Oct; 104(7):1391-7. PubMed ID: 16116605
[TBL] [Abstract][Full Text] [Related]
31. Gene amplification and immunohistochemical expression of ERBB2 and EGFR in cervical carcinogenesis. Correlation with cell-cycle markers and HPV presence.
Conesa-Zamora P; Torres-Moreno D; Isaac MA; Pérez-Guillermo M
Exp Mol Pathol; 2013 Oct; 95(2):151-5. PubMed ID: 23827764
[TBL] [Abstract][Full Text] [Related]
32. Metaplastic breast carcinomas are negative for Her-2 but frequently express EGFR (Her-1): potential relevance to adjuvant treatment with EGFR tyrosine kinase inhibitors?
Leibl S; Moinfar F
J Clin Pathol; 2005 Jul; 58(7):700-4. PubMed ID: 15976335
[TBL] [Abstract][Full Text] [Related]
33. HER2 testing of gynecologic carcinosarcomas: tumor stratification for potential targeted therapy.
Rottmann D; Snir OL; Wu X; Wong S; Hui P; Santin AD; Buza N
Mod Pathol; 2020 Jan; 33(1):118-127. PubMed ID: 31477811
[TBL] [Abstract][Full Text] [Related]
34. Frequent overexpression of the c-kit protein in large cell neuroendocrine carcinoma of the lung.
Araki K; Ishii G; Yokose T; Nagai K; Funai K; Kodama K; Nishiwaki Y; Ochiai A
Lung Cancer; 2003 May; 40(2):173-80. PubMed ID: 12711118
[TBL] [Abstract][Full Text] [Related]
35. Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?
Massard C; Voigt JJ; Laplanche A; Culine S; Lortholary A; Bugat R; Theodore C; Priou F; Kaminsky MC; Lesimple T; Pivot X; Coudert B; Douillard JY; Merrouche Y; Fizazi K
Br J Cancer; 2007 Oct; 97(7):857-61. PubMed ID: 17876336
[TBL] [Abstract][Full Text] [Related]
36. Expression and amplification of therapeutic target genes in retinoblastoma.
Bösch D; Pache M; Simon R; Schraml P; Glatz K; Mirlacher M; Flammer J; Sauter G; Meyer P
Graefes Arch Clin Exp Ophthalmol; 2005 Feb; 243(2):156-62. PubMed ID: 15549365
[TBL] [Abstract][Full Text] [Related]
37. Histopathological features of HER2 overexpression in uterine carcinosarcoma: proposal for requirements in HER2 testing for targeted therapy.
Yoshida H; Nishikawa T; Matsumoto K; Mori M; Hirashima Y; Takehara K; Ariyoshi K; Hasegawa K; Yonemori K
Virchows Arch; 2021 Jun; 478(6):1161-1171. PubMed ID: 33423127
[TBL] [Abstract][Full Text] [Related]
38. HER2 status in lung adenocarcinoma: a comparison of immunohistochemistry, fluorescence in situ hybridization (FISH), dual-ISH, and gene mutations.
Yoshizawa A; Sumiyoshi S; Sonobe M; Kobayashi M; Uehara T; Fujimoto M; Tsuruyama T; Date H; Haga H
Lung Cancer; 2014 Sep; 85(3):373-8. PubMed ID: 25047676
[TBL] [Abstract][Full Text] [Related]
39. L1CAM expression in uterine carcinosarcoma is limited to the epithelial component and may be involved in epithelial-mesenchymal transition.
Versluis M; Plat A; de Bruyn M; Matias-Guiu X; Trovic J; Krakstad C; Nijman HW; Bosse T; de Bock GH; Hollema H
Virchows Arch; 2018 Nov; 473(5):591-598. PubMed ID: 30140948
[TBL] [Abstract][Full Text] [Related]
40. Expression and genomic status of EGFR and ErbB-2 in alveolar and embryonal rhabdomyosarcoma.
Ganti R; Skapek SX; Zhang J; Fuller CE; Wu J; Billups CA; Breitfeld PP; Dalton JD; Meyer WH; Khoury JD
Mod Pathol; 2006 Sep; 19(9):1213-20. PubMed ID: 16729016
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
